Brooklyn, New York Clinical Trials

A listing of Brooklyn, New York clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 517 clinical trials
TKR With and Without the Use of Intra-operative Sensing

The purpose of this study is to determine if there is a difference in clinical outcomes after total knee replacement (TKR) performed with traditional ligament balancing compared to use of intraoperative sensing technology (IOS) to balance ligaments. IOS is used to send real time information to a monitor within the …

total knee replacement
osteoarthritis
Hospital for Special Surgery
 (5.5 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • 1 location
Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate Cancer

This phase II trial compares high-dose rate brachytherapy and stereotactic ablative radiotherapy as monotherapy in treating patients with prostate cancer that has not spread to other parts of the body (localized). High-dose rate brachytherapy delivers radiation directly into the prostate within a few minutes by a single radioactive seed through …

stage iic prostate cancer ajcc v8
prostate specific antigen
stage i prostate cancer
protocol treatment
stage iia prostate cancer ajcc v8
Rutgers New Jersey Medical School
 (9.9 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +1 other locations
Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment

A Phase1/2a Study of Rigosertib plus Nivolumab in Stage IV Lung Adenocarcinoma Patients with KRAS Mutation who Progressed on First-Line Treatment

core needle biopsy
stage iv lung adenocarcinoma
lung adenocarcinoma
nivolumab
kras
Icahn School of Medicine at Mount Sinai
 (7.1 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • 1 location
ATR Inhibitor BAY 1895344 Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer

The purpose of the study is to test how well patients with advanced solid tumors and ovarian cancer respond to treatment with BAY1895344 in combination with niraparib. In addition researchers want to find for patients the optimal dose of BAY1895344 in combination with niraparib, how the drug is tolerated and …

neutrophil count
tumor cells
ATR
prostate cancer
malnutrition
Memorial Sloan-Kettering Cancer Center
 (5.1 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +3 other locations
A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy

Endocrine therapy is the initial treatment for most hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancers. This study will evaluate the use of venetoclax in combination with capecitabine in adult participants with HR+, HER2-, metastatic breast cancer (MBC) who had disease progression following treatment …

endocrine therapy
hormone therapy
epidermal growth factor receptor
breast cancer
metastatic breast cancer
Memorial Sloan Kettering Cancer Center /ID# 214886
 (5.1 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +15 other locations
A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression

Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. It is the most common form of lung cancer, accounting for around 85% of lung cancers. The purpose of this study is to evaluate the safety and efficacy …

epidermal growth factor receptor
stage iv non-small cell lung cancer
non-small cell lung cancer
lymphoma
EGFR
NYU Langone - Laura and Isaac Perlmutter Cancer Center /ID# 218077
 (3.7 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +38 other locations
Heart Transplantation Using Normothermic Regional Perfusion Donation After Circulatory Death

Normothermic regional perfusion (NRP) utilizes Extracorporeal Membrane Oxygenation (ECMO) or cardiopulmonary bypass to reperfuse the heart and other organs in situ after isolation and ligation of the cerebral vessels. In situ resuscitation of the heart has the added advantage of allowing full hemodynamic and echocardiographic assessment of the donor heart …

heart transplantation
NYU Langone Health
 (3.7 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • 1 location
Dose Reduction of Postoperative Radiation for Soft Tissue Sarcoma of the Arms and Legs

The investigators are doing this study to find out whether lowering the dose of postoperative radiation therapy and targeting a smaller area of tissue for treatment is as effective as the standard dose and volume of radiation therapy to control soft tissue sarcoma after surgery. They also want to find …

sarcoma
soft tissue sarcoma
primary tumor
serum pregnancy test
sarcoma of the extremity
Memorial Sloan Kettering Cancer Center
 (5.1 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +6 other locations
Tipifarnib for the Treatment of Advanced Solid Tumors Lymphoma or Histiocytic Disorders With HRAS Gene Alterations a Pediatric MATCH Treatment Trial

This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have spread to other places in the body (advanced), lymphoma, or histiocytic disorders that have HRAS genetic alterations. Tipifarnib may block the growth of cancer cells that have specific genetic changes in …

neutrophil count
total body irradiation
131i-mibg
cancer therapy
recurrent who grade ii glioma
Laura and Isaac Perlmutter Cancer Center at NYU Langone
 (3.7 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +82 other locations
Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas

Subjects with Neurofibromatosis Type 2 (NF2) and progressive vestibular schwannoma (VS) will be treated with crizotinib administered orally. Crizotinib will be taken continuously until disease progression or unacceptable toxicity, in continuous treatment cycles of 28 days each, for a maximum of 12 cycles.

neutrophil count
nf2 gene
measurable disease
crizotinib
multiple meningiomas
New York University Medical Center (Site 200)
 (3.7 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +16 other locations